Protein tyrosine phosphatase 1B (PTP1B) as a potential therapeutic target for neurological disorders
Autor
Olloquequi, Jordi
Cano, Amanda
Sanchez-López, Elena
Carrasco, Marina
Verdaguer, Ester
Fortuna, Ana
Folch, Jaume
Bulló, Mònica
Auladell, Carme
Camins, Antoni
Ettcheto, Miren
Resumen
Protein tyrosine phosphatase 1B (PTP1B) is a typical member of the PTP family, considered a direct negative regulator of several receptor and receptor-associated tyrosine kinases. This widely localized enzyme has been involved in the pathophysiology of several diseases. More recently, PTP1B has attracted attention in the field of neuroscience, since its activation in brain cells can lead to schizophrenia-like behaviour deficits, anxiety-like effects, neurodegeneration, neuroinflammation and depression. Conversely, PTP1B inhibition has been shown to prevent microglial activation, thus exerting a potent anti-inflammatory effect and has also shown potential to increase the cognitive process through the stimulation of hippocampal insulin, leptin and BDNF/TrkB receptors. Notwithstanding, most research on the clinical efficacy of targeting PTP1B has been developed in the field of obesity and type 2 diabetes mellitus (TD2M). However, despite the link existing between these metabolic alterations and neurodegeneration, no clinical trials assessing the neurological advantages of PTP1B inhibition have been performed yet. Preclinical studies, though, have provided strong evidence that targeting PTP1B could allow to reach different pathophysiological mechanisms at once. herefore, specific interventions or trials should be designed to modulate PTP1B activity in brain, since it is a promising strategy to decelerate or prevent neurodegeneration in aged individuals, among other neurological diseases. The present paper fails to include all neurological conditions in which PTP1B could have a role; instead, it focuses on those which have been related to metabolic alterations and neurodegenerative processes. Moreover, only preclinical data is discussed, since clinical studies on the potential of PTP1B inhibition for treating neurological diseases are still required. © 2022
Colecciones
Ítems relacionados
Mostrando ítems relacionados por Título, autor o materia.
-
Article
A novel rhein-huprine hybrid ameliorates disease-modifying properties in preclinical mice model of Alzheimer’s disease exacerbated with high fat diet (2024)
Espinosa-Jiménez, Triana; Cano, Amanda; Sánchez-López, Elena; Olloquequi, Jordi; Folch, Jaume; Bulló, Mònica; Verdaguer, Ester; Auladell, Carme; Pont, Caterina; Muñoz-Torrero, Diego; ... (BioMed Central Ltd, 2023)Background: Alzheimer’s disease (AD) is characterized by a polyetiological origin. Despite the global burden of AD and the advances made in AD drug research and development, the cure of the disease remains elusive, since ... -
Article
Impact of New Drugs for Therapeutic Intervention in Alzheimer’s Disease (2024)
Olloquequi, Jordi; Ettcheto, Miren; Cano, Amanda; Sanchez-López, Elena; Carrasco, Marina; Espinosa, Triana; Beas-Zarate, Carlos; Gudiño-Cabrera, Graciela; Ureña-Guerrero, Monica E.; Verdaguer, Ester; ... (Bioscience Research Institute, 2022)The increases in population ageing and growth are leading to a boosting in the number of people living with dementia, Alzheimer’s disease (AD) being the most common cause. In spite of decades of intensive research, no cure ... -
Article
Dexibuprofen ameliorates peripheral and central risk factors associated with Alzheimer’s disease in metabolically stressed APPswe/PS1dE9 mice (2021)
Ettcheto, Miren; Sánchez-López, Elena; Cano, Amanda; Carrasco, Marina; Herrera, Katherine; Manzine, Patricia Regina; Espinosa-Jiménez, Triana; Busquets, Oriol; Verdaguer, Ester; Olloquequi, Jordi; ... (BioMed Central Ltd, 2021-12)Background: Several studies stablished a relationship between metabolic disturbances and Alzheimer´s disease (AD) where inflammation plays a pivotal role. However, mechanisms involved still remain unclear. In the present ...